Dana Parsons‐Rich

Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study

G Schmieder, Zoé Kececioglu Draelos, David M. Pariser et al. · British Journal of Dermatology · 2017 · 93 citations

Medicine, Pharmacology, Pharmacotherapy +11

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled Dose‐Ranging</scp> Trial

Daniel J. Wallace, Thomas Dörner, David S. Pisetsky et al. · ACR Open Rheumatology · 2022 · 46 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis

Xavier Montalbán, Daniel J. Wallace, Mark C. Genovese et al. · Journal of Neurology Neurosurgery & Psychiatry · 2022 · 33 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Phase 1 dose‐escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXaI16L)

Dana Parsons‐Rich, Fei Hua, Guozhong Li et al. · Journal of Thrombosis and Haemostasis · 2017 · 26 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +9